Table 1.

Baseline characteristics of study cohort

Patient Characteristics	Total Cohort (N=26)
Age, mean (SD)	50.7 (13.6)
Disease duration* (years), (median, IQR)	0.8 [0.6, 1.2]
Sex, female, n (%)	20 (77%)
Race, n (%)
White	19 (73%)
Black	5 (19%)
Asian	2 (8%)
SSc-specific autoantibodies, positive, n (%)
Anti-topoisomerase I (Scl-70)	6 (23%)
Anti-centromere	2 (8%)
Anti-RNA polymerase III	15 (58%)
ILD present, n (%)	8 (31%)
FVC %-predicted, mean (SD)	86 (16)
DLCO %-predicted, mean (SD)	79 (17)
History of renal crisis, n (%)	2 (8%)
MRSS, total, median (IQR)	25 [22, 31]
MRSS, forearm (local), mean (SD)	2 (0.75)
Physician Global Assessment (0–10), median (IQR)	5.8 [5.0, 6.8]
Patient Global Assessment (0–10), median (IQR)	2.9 [1.1, 4.7]
HAQ-DI, mean (SD)	0.85 (0.59)

^*Time since first non-Raynaud’s disease symptom. SSc=systemic sclerosis; ILD=interstitial lung disease; FVC=forced vital capacity; DLCO=diffusing capacity for carbon monoxide in the lungs; MRSS=modified Rodnan skin score; HAQ-DI=Health Assessment Questionnaire Disability Index; CRISS=Combined Response Index in Systemic Sclerosis; IQR=interquartile range.